Why the study?
Prolonged expression of CRISPR-Cas9 and gRNA from viral vectors can cause off-target mutagenesis and immunogenicity, necessitating a transient delivery system for therapeutic genome editing.
Does NanoMEDIC induce efficient genome editing and exon skipping in hard-to-transfect cells and in vivo models?
Does NanoMEDIC induce efficient genome editing and exon skipping in hard-to-transfect cells and in vivo models?
NanoMEDIC provides an efficient, transient delivery system for CRISPR-Cas9 genome editing, demonstrating high exon skipping efficiency in DMD models in vitro and in vivo.
Answers are grounded in this paper and cite their sources.
May inform DMD exon-skipping strategies; leaves open human translation from animal data.
Prolonged expression of the CRISPR-Cas9 nuclease and gRNA from viral vectors may cause off-target mutagenesis and immunogenicity. Thus, a transient delivery system is needed for therapeutic genome editing applications. Here, we develop an extracellular nanovesicle-based ribonucleoprotein delivery system named NanoMEDIC by utilizing two distinct homing mechanisms. Chemical induced dimerization recruits Cas9 protein into extracellular nanovesicles, and then a viral RNA packaging signal and two self-cleaving riboswitches tether and release sgRNA into nanovesicles. We demonstrate efficient genome editing in various hard-to-transfect cell types, including human induced pluripotent stem (iPS) cells, neurons, and myoblasts. NanoMEDIC also achieves over 90% exon skipping efficiencies in skeletal muscle cells derived from Duchenne muscular dystrophy (DMD) patient iPS cells. Finally, single intramuscular injection of NanoMEDIC induces permanent genomic exon skipping in a luciferase reporter mouse and in mdx mice, indicating its utility for in vivo genome editing therapy of DMD and beyond.
No takes yet. Share an insight, caveat, or question.
Gee et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: